| March 2, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| March 2, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| March 2, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 2, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 2, 2026 |
SNY |
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa |
Trial Milestone |
Phase 3 |
| March 2, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 2, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 2, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 2, 2026 |
NUVB |
Quarterly results filed (8-K) |
Earnings |
— |
| March 2, 2026 |
EYPT |
8-K filed: Other event |
Filing |
— |
| March 2, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| March 2, 2026 |
NTLA |
8-K filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| March 2, 2026 |
VIR |
8-K filed: Other event |
Filing |
— |
| March 2, 2026 |
URGN |
Quarterly results filed (8-K) |
Earnings |
— |
| March 2, 2026 |
URGN |
8-K filed: Material agreement |
Corporate |
— |
| March 2, 2026 |
RYTM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| March 2, 2026 |
DYN |
Quarterly results filed (8-K) |
Earnings |
— |
| March 2, 2026 |
GKOS |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 2, 2026 |
BLTE |
6-K filed: Foreign issuer report |
Filing |
— |
| March 2, 2026 |
UTHR |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 2, 2026 |
QURE |
Quarterly results filed (8-K) |
Earnings |
— |
| March 2, 2026 |
TYRA |
Quarterly results filed (8-K) |
Earnings |
— |
| March 2, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| March 2, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| March 2, 2026 |
CERS |
Quarterly results filed (8-K) |
Earnings |
— |
| March 3, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| March 3, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 3, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| March 3, 2026 |
GILD |
Study of GS-3242 in Participants With HIV-1; Substudy-05 |
Trial Milestone |
Phase 1 |
| March 3, 2026 |
INCY |
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia |
Trial Milestone |
Phase 2 |
| March 3, 2026 |
KPTI |
8-K filed: Material agreement, Other event |
Corporate |
— |
| March 3, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| March 3, 2026 |
CORT |
Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects |
Trial Milestone |
Phase 1 |
| March 3, 2026 |
OCS |
6-K filed: Foreign issuer report |
Filing |
— |
| March 3, 2026 |
DCTH |
8-K filed: Other event |
Filing |
— |
| March 3, 2026 |
SRRK |
Quarterly results filed (8-K) |
Earnings |
— |
| March 3, 2026 |
SRRK |
Quarterly results filed (8-K) |
Earnings |
— |
| March 3, 2026 |
AMLX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 3, 2026 |
STOK |
8-K filed: Leadership change |
Corporate |
— |
| March 3, 2026 |
NTHI |
8-K filed: Material agreement |
Corporate |
— |
| March 3, 2026 |
IMNM |
Quarterly results filed (8-K) |
Earnings |
— |
| March 3, 2026 |
RIGL |
Quarterly results filed (8-K) |
Earnings |
— |
| March 4, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| March 4, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 4, 2026 |
ABBV |
8-K filed: Other event |
Filing |
— |
| March 4, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| March 4, 2026 |
GILD |
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis |
Trial Milestone |
Phase 2 |
| March 4, 2026 |
ALNY |
8-K filed: Leadership change |
Corporate |
— |
| March 4, 2026 |
VSTM |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 4, 2026 |
EYPT |
Quarterly results filed (8-K) |
Earnings |
— |
| March 4, 2026 |
OCGN |
8-K filed: Other event |
Filing |
— |
| March 4, 2026 |
OCGN |
Quarterly results filed (8-K) |
Earnings |
— |
| March 4, 2026 |
VIR |
8-K filed: Leadership change |
Corporate |
— |
| March 4, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| March 4, 2026 |
OCS |
6-K filed: Foreign issuer report |
Filing |
— |
| March 4, 2026 |
OCS |
Results filed (20-F) |
Earnings |
— |
| March 4, 2026 |
TYRA |
8-K filed: Other event |
Filing |
— |
| March 4, 2026 |
CLRB |
Quarterly results filed (8-K) |
Earnings |
— |
| March 4, 2026 |
MAIA |
8-K filed: Material agreement, Other event |
Corporate |
— |
| March 4, 2026 |
NTHI |
8-K filed: Other event |
Filing |
— |
| March 4, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| March 4, 2026 |
LPCN |
8-K filed: Other event |
Filing |
— |
| March 4, 2026 |
TCRX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 4, 2026 |
XNCR |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 5, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 5, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 5, 2026 |
BIIB |
A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled Diranersen (BIIB080) Co-administered With Diranersen in Healthy Adults |
Trial Milestone |
Phase 1 |
| March 5, 2026 |
MRNA |
8-K filed: Material agreement |
Corporate |
— |
| March 5, 2026 |
ACAD |
8-K filed: Leadership change |
Corporate |
— |
| March 5, 2026 |
LQDA |
Quarterly results filed (8-K) |
Earnings |
— |
| March 5, 2026 |
RGNX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 5, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| March 5, 2026 |
MDWD |
Results filed (20-F) |
Earnings |
— |
| March 5, 2026 |
MDWD |
6-K filed: Foreign issuer report |
Filing |
— |
| March 5, 2026 |
AVIR |
Quarterly results filed (8-K) |
Earnings |
— |
| March 5, 2026 |
IVVD |
Quarterly results filed (8-K) |
Earnings |
— |
| March 5, 2026 |
AVBP |
Quarterly results filed (8-K) |
Earnings |
— |
| March 5, 2026 |
TNGX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 5, 2026 |
IMTX |
Results filed (20-F) |
Earnings |
— |
| March 5, 2026 |
IMTX |
6-K filed: Foreign issuer report |
Filing |
— |
| March 5, 2026 |
KURA |
Quarterly results filed (8-K) |
Earnings |
— |
| March 5, 2026 |
ALT |
Quarterly results filed (8-K) |
Earnings |
— |
| March 5, 2026 |
INTS |
Quarterly results filed (8-K) |
Earnings |
— |
| March 5, 2026 |
CLYM |
Quarterly results filed (8-K) |
Earnings |
— |
| March 5, 2026 |
RVPH |
8-K filed: Other event |
Filing |
— |
| March 5, 2026 |
CRMD |
Quarterly results filed (8-K) |
Earnings |
— |
| March 5, 2026 |
LXRX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 5, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| March 5, 2026 |
OTLK |
8-K filed: Other event |
Filing |
— |
| March 6, 2026 |
AZN |
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations |
Trial Milestone |
Phase 3 |
| March 6, 2026 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| March 6, 2026 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| March 6, 2026 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| March 6, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 6, 2026 |
GSK |
Results filed (20-F) |
Earnings |
— |
| March 6, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 6, 2026 |
INCY |
8-K filed: Other event |
Filing |
— |
| March 6, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| March 6, 2026 |
SLDB |
Quarterly results filed (8-K) |
Earnings |
— |
| March 6, 2026 |
NRIX |
8-K filed: Other event |
Filing |
— |
| March 6, 2026 |
IMRX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 6, 2026 |
INTS |
8-K filed: Other event |
Filing |
— |
| March 6, 2026 |
NTHI |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 6, 2026 |
CRMD |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 6, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| March 6, 2026 |
ALZN |
8-K filed: Material agreement |
Corporate |
— |
| March 9, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 9, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 9, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 9, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 9, 2026 |
BIIB |
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 |
Trial Milestone |
Phase 2 |
| March 9, 2026 |
IONS |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| March 9, 2026 |
XENE |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 9, 2026 |
DNTH |
Quarterly results filed (8-K) |
Earnings |
— |
| March 9, 2026 |
SGP |
8-K filed: Other event |
Filing |
— |
| March 9, 2026 |
RNAC |
Quarterly results filed (8-K) |
Earnings |
— |
| March 9, 2026 |
TRVI |
8-K filed: Other event |
Filing |
— |
| March 9, 2026 |
CRBP |
Quarterly results filed (8-K) |
Earnings |
— |
| March 9, 2026 |
UTHR |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| March 9, 2026 |
LYEL |
8-K filed: Leadership change |
Corporate |
— |
| March 9, 2026 |
VERA |
8-K filed: Leadership change |
Corporate |
— |
| March 9, 2026 |
RLMD |
8-K filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| March 9, 2026 |
MBX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| March 9, 2026 |
LRMR |
8-K filed: Other event |
Filing |
— |
| March 9, 2026 |
BFRI |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 9, 2026 |
ABEO |
8-K filed: Other event |
Filing |
— |
| March 9, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| March 9, 2026 |
MLYS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| March 9, 2026 |
SPRB |
Quarterly results filed (8-K) |
Earnings |
— |
| March 9, 2026 |
EDIT |
Quarterly results filed (8-K) |
Earnings |
— |
| March 9, 2026 |
WST |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| March 10, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| March 10, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| March 10, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 10, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| March 10, 2026 |
BIIB |
A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways |
Trial Milestone |
Phase 1 |
| March 10, 2026 |
BNTX |
Results filed (20-F) |
Earnings |
— |
| March 10, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| March 10, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| March 10, 2026 |
VNDA |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 10, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| March 10, 2026 |
RAPP |
Quarterly results filed (8-K) |
Earnings |
— |
| March 10, 2026 |
TARA |
Quarterly results filed (8-K) |
Earnings |
— |
| March 10, 2026 |
LBRX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| March 10, 2026 |
TENX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 10, 2026 |
IRD |
Quarterly results filed (8-K) |
Earnings |
— |
| March 10, 2026 |
CAPR |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| March 10, 2026 |
VTVT |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 10, 2026 |
VTVT |
Quarterly results filed (8-K) |
Earnings |
— |
| March 10, 2026 |
SYRE |
A Study of SPY001-001 in Healthy Volunteers |
Trial Milestone |
Phase 1 |
| March 10, 2026 |
MPLT |
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) |
Trial Milestone |
Phase 2 |
| March 10, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| March 10, 2026 |
LPCN |
Quarterly results filed (8-K) |
Earnings |
— |
| March 10, 2026 |
CGEM |
Quarterly results filed (8-K) |
Earnings |
— |
| March 10, 2026 |
QTTB |
Quarterly results filed (8-K) |
Earnings |
— |
| March 11, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 11, 2026 |
ARGX |
A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). |
Trial Milestone |
Phase 3 |
| March 11, 2026 |
BIIB |
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age |
Trial Milestone |
Phase 2 |
| March 11, 2026 |
BIIB |
8-K filed: Leadership change |
Corporate |
— |
| March 11, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| March 11, 2026 |
QNRX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| March 11, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| March 11, 2026 |
VRCA |
Quarterly results filed (8-K) |
Earnings |
— |
| March 11, 2026 |
VTGN |
8-K filed: Other event |
Filing |
— |
| March 11, 2026 |
SLS |
8-K filed: Other event |
Filing |
— |
| March 11, 2026 |
CRSP |
8-K filed: Other event |
Filing |
— |
| March 11, 2026 |
SGMT |
Quarterly results filed (8-K) |
Earnings |
— |
| March 11, 2026 |
NERV |
Quarterly results filed (8-K) |
Earnings |
— |
| March 11, 2026 |
BTMD |
Quarterly results filed (8-K) |
Earnings |
— |
| March 11, 2026 |
OTLK |
8-K filed: Leadership change |
Corporate |
— |
| March 12, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| March 12, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 12, 2026 |
BNTX |
Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers |
Trial Milestone |
Phase 1/Phase 2 |
| March 12, 2026 |
RARE |
8-K filed: Other event |
Filing |
— |
| March 12, 2026 |
XENE |
8-K filed: Material agreement, Other event |
Corporate |
— |
| March 12, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| March 12, 2026 |
CADL |
Quarterly results filed (8-K) |
Earnings |
— |
| March 12, 2026 |
DNTH |
8-K filed: Material agreement |
Corporate |
— |
| March 12, 2026 |
NKTR |
Quarterly results filed (8-K) |
Earnings |
— |
| March 12, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 12, 2026 |
SLDB |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| March 12, 2026 |
LYEL |
Quarterly results filed (8-K) |
Earnings |
— |
| March 12, 2026 |
MBX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 12, 2026 |
PRQR |
Results filed (20-F) |
Earnings |
— |
| March 12, 2026 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| March 12, 2026 |
CAPR |
Quarterly results filed (8-K) |
Earnings |
— |
| March 12, 2026 |
CRVS |
Quarterly results filed (8-K) |
Earnings |
— |
| March 12, 2026 |
HALO |
8-K filed: Leadership change |
Corporate |
— |
| March 12, 2026 |
MLYS |
Quarterly results filed (8-K) |
Earnings |
— |
| March 12, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 12, 2026 |
ERAS |
Quarterly results filed (8-K) |
Earnings |
— |
| March 12, 2026 |
CNSY |
8-K filed: Other event |
Filing |
— |
| March 12, 2026 |
CNSY |
Quarterly results filed (8-K) |
Earnings |
— |
| March 12, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| March 12, 2026 |
SXTP |
8-K filed: Other event |
Filing |
— |
| March 12, 2026 |
ALLO |
Quarterly results filed (8-K) |
Earnings |
— |
| March 13, 2026 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| March 13, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 13, 2026 |
XENE |
8-K filed: Other event |
Filing |
— |
| March 13, 2026 |
SVRA |
8-K filed: Material agreement |
Corporate |
— |
| March 13, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 13, 2026 |
ORKA |
ORKA-001 in Healthy Volunteers |
Trial Milestone |
Phase 1 |
| March 13, 2026 |
CRVS |
8-K filed: Material agreement |
Corporate |
— |
| March 13, 2026 |
NGEN |
6-K filed: Foreign issuer report |
Filing |
— |
| March 13, 2026 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| March 13, 2026 |
ACIU |
Results filed (20-F) |
Earnings |
— |
| March 13, 2026 |
SXTP |
8-K filed: Other event |
Filing |
— |
| March 15, 2026 |
ABBV |
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China |
Trial Milestone |
Phase 4 |
| March 15, 2026 |
SVA |
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women |
Trial Milestone |
Phase 3 |
| March 15, 2026 |
AXSM |
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms |
Trial Milestone |
Phase 4 |
| March 15, 2026 |
BCYC |
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies |
Trial Milestone |
Phase 1/Phase 2 |
| March 15, 2026 |
OLMA |
A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients |
Trial Milestone |
Phase 1 |
| March 15, 2026 |
ACIU |
[18F]ACI-15916 PET in α-synucleinopathies |
Trial Milestone |
EARLY_Phase 1 |
| March 15, 2026 |
CGEM |
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| March 16, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| March 16, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 16, 2026 |
GILD |
Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated |
Trial Milestone |
Phase 2/Phase 3 |
| March 16, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| March 16, 2026 |
BMRN |
8-K filed: Other event |
Filing |
— |
| March 16, 2026 |
ZBIO |
Quarterly results filed (8-K) |
Earnings |
— |
| March 16, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| March 16, 2026 |
VIR |
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection |
Trial Milestone |
Phase 2 |
| March 16, 2026 |
ANVS |
Quarterly results filed (8-K) |
Earnings |
— |
| March 16, 2026 |
RYTM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| March 16, 2026 |
VTGN |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 16, 2026 |
LBRX |
8-K filed: Leadership change |
Corporate |
— |
| March 16, 2026 |
OLMA |
Quarterly results filed (8-K) |
Earnings |
— |
| March 16, 2026 |
RLAY |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| March 16, 2026 |
ANRO |
8-K filed: Material agreement, Other event |
Corporate |
— |
| March 16, 2026 |
ANRO |
Quarterly results filed (8-K) |
Earnings |
— |
| March 16, 2026 |
KYNB |
Quarterly results filed (8-K) |
Earnings |
— |
| March 16, 2026 |
CRSP |
8-K filed: Material agreement |
Corporate |
— |
| March 16, 2026 |
CATX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 16, 2026 |
COYA |
Quarterly results filed (8-K) |
Earnings |
— |
| March 16, 2026 |
OTLK |
8-K filed: Material agreement, Other event |
Corporate |
— |
| March 16, 2026 |
AGEN |
Quarterly results filed (8-K) |
Earnings |
— |
| March 16, 2026 |
CERS |
8-K filed: Leadership change |
Corporate |
— |
| March 16, 2026 |
BDTX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 17, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| March 17, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 17, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 17, 2026 |
INCY |
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) |
Trial Milestone |
Phase 3 |
| March 17, 2026 |
AGIO |
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) |
Trial Milestone |
Phase 2 |
| March 17, 2026 |
CLDX |
A Study of Barzolvolimab in Patients With Prurigo Nodularis |
Trial Milestone |
Phase 2 |
| March 17, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| March 17, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| March 17, 2026 |
BCYC |
Quarterly results filed (8-K) |
Earnings |
— |
| March 17, 2026 |
TRVI |
Quarterly results filed (8-K) |
Earnings |
— |
| March 17, 2026 |
AVBP |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| March 17, 2026 |
ABEO |
Quarterly results filed (8-K) |
Earnings |
— |
| March 17, 2026 |
VALN |
Results filed (20-F) |
Earnings |
— |
| March 17, 2026 |
NTHI |
8-K filed: Material agreement, Leadership change, Reg FD disclosure |
Corporate |
— |
| March 17, 2026 |
SMNR |
8-K filed: Leadership change |
Corporate |
— |
| March 17, 2026 |
ALDX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| March 17, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| March 17, 2026 |
GOSS |
Quarterly results filed (8-K) |
Earnings |
— |
| March 17, 2026 |
CRIS |
8-K filed: Leadership change |
Corporate |
— |
| March 18, 2026 |
NVS |
6-K filed: Foreign issuer report |
Filing |
— |
| March 18, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| March 18, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 18, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| March 18, 2026 |
FDMT |
Quarterly results filed (8-K) |
Earnings |
— |
| March 18, 2026 |
VTRS |
A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male Participants |
Trial Milestone |
Phase 1 |
| March 18, 2026 |
VTGN |
8-K filed: Leadership change |
Corporate |
— |
| March 18, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 18, 2026 |
PROK |
Quarterly results filed (8-K) |
Earnings |
— |
| March 18, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| March 18, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 18, 2026 |
GNPX |
8-K filed: Other event |
Filing |
— |
| March 19, 2026 |
LLY |
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder |
Trial Milestone |
Phase 2 |
| March 19, 2026 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| March 19, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 19, 2026 |
ABBV |
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) |
Trial Milestone |
Phase 4 |
| March 19, 2026 |
ARGX |
Results filed (20-F) |
Earnings |
— |
| March 19, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| March 19, 2026 |
TSHA |
Quarterly results filed (8-K) |
Earnings |
— |
| March 19, 2026 |
HUMA |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| March 19, 2026 |
HUMA |
Quarterly results filed (8-K) |
Earnings |
— |
| March 19, 2026 |
ALMS |
Quarterly results filed (8-K) |
Earnings |
— |
| March 19, 2026 |
ELDN |
Quarterly results filed (8-K) |
Earnings |
— |
| March 19, 2026 |
SLS |
Quarterly results filed (8-K) |
Earnings |
— |
| March 19, 2026 |
LRMR |
Quarterly results filed (8-K) |
Earnings |
— |
| March 19, 2026 |
GNLX |
8-K filed: Material agreement |
Corporate |
— |
| March 19, 2026 |
LONA |
8-K filed: Leadership change, Other event |
Corporate |
— |
| March 19, 2026 |
BFRI |
Quarterly results filed (8-K) |
Earnings |
— |
| March 19, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| March 19, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| March 19, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 19, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 19, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 19, 2026 |
RVPH |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| March 19, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 19, 2026 |
MBRX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 19, 2026 |
ACRV |
Quarterly results filed (8-K) |
Earnings |
— |
| March 19, 2026 |
CRIS |
Quarterly results filed (8-K) |
Earnings |
— |
| March 20, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| March 20, 2026 |
PFE |
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies |
Trial Milestone |
Phase 1 |
| March 20, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 20, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 20, 2026 |
ARGX |
A Study to Assess the Safety of ARGX-213 in Healthy Volunteers |
Trial Milestone |
Phase 1 |
| March 20, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| March 20, 2026 |
TGTX |
8-K filed: Material agreement |
Corporate |
— |
| March 20, 2026 |
EYPT |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 20, 2026 |
OCGN |
8-K filed: Other event |
Filing |
— |
| March 20, 2026 |
IOVA |
8-K filed: Leadership change |
Corporate |
— |
| March 20, 2026 |
RGNX |
8-K filed: Material agreement |
Corporate |
— |
| March 20, 2026 |
RYTM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| March 20, 2026 |
RLMD |
Quarterly results filed (8-K) |
Earnings |
— |
| March 20, 2026 |
PBH |
8-K filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| March 20, 2026 |
CLLS |
Results filed (20-F) |
Earnings |
— |
| March 20, 2026 |
CLLS |
6-K filed: Foreign issuer report |
Filing |
— |
| March 20, 2026 |
ALZN |
8-K filed: Listing / standard notice |
Corporate |
— |
| March 20, 2026 |
SXTP |
8-K filed: Other event |
Filing |
— |
| March 23, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| March 23, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 23, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 23, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 23, 2026 |
ABBV |
A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers |
Trial Milestone |
Phase 1 |
| March 23, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 23, 2026 |
INBS |
8-K filed: Leadership change, Other event |
Corporate |
— |
| March 23, 2026 |
INSM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| March 23, 2026 |
CABA |
Quarterly results filed (8-K) |
Earnings |
— |
| March 23, 2026 |
RCUS |
8-K filed: Leadership change |
Corporate |
— |
| March 23, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 23, 2026 |
IMNN |
8-K filed: Other event |
Filing |
— |
| March 23, 2026 |
ABVX |
Results filed (20-F) |
Earnings |
— |
| March 23, 2026 |
ABVX |
6-K filed: Foreign issuer report |
Filing |
— |
| March 23, 2026 |
INTS |
8-K filed: Other event |
Filing |
— |
| March 23, 2026 |
RNXT |
8-K filed: Material agreement, Other event |
Corporate |
— |
| March 23, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| March 23, 2026 |
NTHI |
8-K filed: Material agreement |
Corporate |
— |
| March 23, 2026 |
BLRX |
6-K filed: Foreign issuer report |
Filing |
— |
| March 23, 2026 |
BLRX |
Results filed (20-F) |
Earnings |
— |
| March 23, 2026 |
TPST |
8-K filed: Material agreement |
Corporate |
— |
| March 23, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 24, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 24, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| March 24, 2026 |
BNTX |
6-K filed: Foreign issuer report |
Filing |
— |
| March 24, 2026 |
KPTI |
8-K filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| March 24, 2026 |
GRFS |
6-K filed: Foreign issuer report |
Filing |
— |
| March 24, 2026 |
OCGN |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 24, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| March 24, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| March 24, 2026 |
CMPS |
Quarterly results filed (8-K) |
Earnings |
— |
| March 24, 2026 |
ALMS |
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage |
Trial Milestone |
Phase 1 |
| March 24, 2026 |
AMLX |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 24, 2026 |
NGNE |
Quarterly results filed (8-K) |
Earnings |
— |
| March 24, 2026 |
BCTX |
Combination Study of SV-BR-1-GM With Retifanlimab |
Trial Milestone |
Phase 1/Phase 2 |
| March 24, 2026 |
TTRX |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| March 24, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| March 24, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| March 24, 2026 |
ACHV |
Quarterly results filed (8-K) |
Earnings |
— |
| March 24, 2026 |
BIOA |
Quarterly results filed (8-K) |
Earnings |
— |
| March 25, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| March 25, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 25, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 25, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 25, 2026 |
IONS |
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) |
Trial Milestone |
Phase 3 |
| March 25, 2026 |
ANVS |
8-K filed: Leadership change |
Corporate |
— |
| March 25, 2026 |
CORT |
8-K filed: Other event |
Filing |
— |
| March 25, 2026 |
DNLI |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 25, 2026 |
AWHL |
8-K/A filed: Material agreement |
Corporate |
— |
| March 25, 2026 |
ORKA |
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis |
Trial Milestone |
Phase 2 |
| March 25, 2026 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| March 25, 2026 |
RXRX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| March 25, 2026 |
BYSI |
Quarterly results filed (8-K) |
Earnings |
— |
| March 25, 2026 |
OTLK |
8-K filed: Other event |
Filing |
— |
| March 25, 2026 |
PGEN |
Quarterly results filed (8-K) |
Earnings |
— |
| March 25, 2026 |
KPRX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 25, 2026 |
NKTX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 25, 2026 |
MAZE |
Quarterly results filed (8-K) |
Earnings |
— |
| March 26, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 26, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 26, 2026 |
NVO |
A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy Men |
Trial Milestone |
Phase 1 |
| March 26, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 26, 2026 |
INCY |
8-K filed: Leadership change |
Corporate |
— |
| March 26, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| March 26, 2026 |
QNRX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 26, 2026 |
CANF |
Results filed (20-F) |
Earnings |
— |
| March 26, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| March 26, 2026 |
RYTM |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| March 26, 2026 |
DNTH |
8-K filed: Other event |
Filing |
— |
| March 26, 2026 |
MGTX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 26, 2026 |
LBRX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 26, 2026 |
SGP |
Quarterly results filed (8-K) |
Earnings |
— |
| March 26, 2026 |
IKT |
Quarterly results filed (8-K) |
Earnings |
— |
| March 26, 2026 |
GERN |
8-K filed: Leadership change |
Corporate |
— |
| March 26, 2026 |
NVCR |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 26, 2026 |
KYTX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 26, 2026 |
LONA |
Quarterly results filed (8-K) |
Earnings |
— |
| March 26, 2026 |
MPLT |
Quarterly results filed (8-K) |
Earnings |
— |
| March 26, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| March 26, 2026 |
BLRX |
6-K filed: Foreign issuer report |
Filing |
— |
| March 26, 2026 |
WVE |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| March 26, 2026 |
LKFT |
Results filed (20-F) |
Earnings |
— |
| March 26, 2026 |
AGEN |
8-K filed: Other event |
Filing |
— |
| March 26, 2026 |
CNSY |
8-K filed: Leadership change |
Corporate |
— |
| March 26, 2026 |
NKTX |
8-K filed: Other event |
Filing |
— |
| March 27, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| March 27, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 27, 2026 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| March 27, 2026 |
REGN |
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) |
Trial Milestone |
Phase 2 |
| March 27, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 27, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 27, 2026 |
MRNA |
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age |
Trial Milestone |
Phase 3 |
| March 27, 2026 |
KPTI |
8-K filed: Other event |
Filing |
— |
| March 27, 2026 |
KOD |
8-K filed: Other event |
Filing |
— |
| March 27, 2026 |
OCGN |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 27, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| March 27, 2026 |
VOR |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| March 27, 2026 |
MAIA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| March 27, 2026 |
INTS |
Quarterly results filed (8-K) |
Earnings |
— |
| March 27, 2026 |
RNXT |
8-K filed: Leadership change |
Corporate |
— |
| March 27, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| March 27, 2026 |
BLRX |
Results filed (20-F/A) |
Earnings |
— |
| March 27, 2026 |
EDIT |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| March 27, 2026 |
QTTB |
8-K filed: Material agreement |
Corporate |
— |
| March 30, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 30, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 30, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 30, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 30, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| March 30, 2026 |
INCY |
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) |
Trial Milestone |
Phase 3 |
| March 30, 2026 |
INCY |
8-K filed: Leadership change |
Corporate |
— |
| March 30, 2026 |
RARE |
8-K filed: Other event |
Filing |
— |
| March 30, 2026 |
FDMT |
8-K filed: Leadership change |
Corporate |
— |
| March 30, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| March 30, 2026 |
MANE |
Quarterly results filed (8-K) |
Earnings |
— |
| March 30, 2026 |
EIKN |
Quarterly results filed (8-K) |
Earnings |
— |
| March 30, 2026 |
BSX |
8-K filed: Other event |
Filing |
— |
| March 30, 2026 |
ANNX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 30, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| March 30, 2026 |
TARA |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 30, 2026 |
RNAC |
8-K filed: Leadership change |
Corporate |
— |
| March 30, 2026 |
MDWD |
6-K filed: Foreign issuer report |
Filing |
— |
| March 30, 2026 |
UTHR |
8-K filed: Other event |
Filing |
— |
| March 30, 2026 |
ALMS |
8-K filed: Other event |
Filing |
— |
| March 30, 2026 |
OTLC |
8-K filed: Other event |
Filing |
— |
| March 30, 2026 |
OTLC |
8-K filed: Other event |
Filing |
— |
| March 30, 2026 |
BCAX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 30, 2026 |
AURA |
Quarterly results filed (8-K) |
Earnings |
— |
| March 30, 2026 |
LXEO |
Quarterly results filed (8-K) |
Earnings |
— |
| March 30, 2026 |
RNXT |
Quarterly results filed (8-K) |
Earnings |
— |
| March 30, 2026 |
RVPH |
Quarterly results filed (8-K) |
Earnings |
— |
| March 30, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| March 30, 2026 |
TPST |
Quarterly results filed (8-K) |
Earnings |
— |
| March 30, 2026 |
ENSC |
Quarterly results filed (8-K) |
Earnings |
— |
| March 30, 2026 |
ENSC |
8-K filed: Leadership change |
Corporate |
— |
| March 30, 2026 |
FTH |
Quarterly results filed (8-K) |
Earnings |
— |
| March 30, 2026 |
LTRN |
Quarterly results filed (8-K) |
Earnings |
— |
| March 31, 2026 |
AZN |
Results filed (6-K) |
Earnings |
— |
| March 31, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| March 31, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| March 31, 2026 |
BIIB |
8-K filed: Material agreement, Other event |
Corporate |
— |
| March 31, 2026 |
IBRX |
8-K filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| March 31, 2026 |
ZBIO |
8-K filed: Material agreement, Other event |
Corporate |
— |
| March 31, 2026 |
KOD |
Quarterly results filed (8-K) |
Earnings |
— |
| March 31, 2026 |
PVLA |
Quarterly results filed (8-K) |
Earnings |
— |
| March 31, 2026 |
DNLI |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 31, 2026 |
IMUX |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| March 31, 2026 |
BLTE |
6-K filed: Foreign issuer report |
Filing |
— |
| March 31, 2026 |
BLTE |
Results filed (20-F) |
Earnings |
— |
| March 31, 2026 |
IMNN |
Quarterly results filed (8-K) |
Earnings |
— |
| March 31, 2026 |
SRRK |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| March 31, 2026 |
ORIC |
8-K filed: Other event |
Filing |
— |
| March 31, 2026 |
MAIA |
8-K filed: Other event |
Filing |
— |
| March 31, 2026 |
LONA |
8-K/A filed: Acquisition completed |
Corporate |
— |
| March 31, 2026 |
ORMP |
8-K filed: Material agreement, Acquisition completed |
Corporate |
— |
| March 31, 2026 |
OMER |
Quarterly results filed (8-K) |
Earnings |
— |
| March 31, 2026 |
BCTX |
8-K filed: Reg FD disclosure |
Filing |
— |
| March 31, 2026 |
TTRX |
Quarterly results filed (8-K) |
Earnings |
— |
| March 31, 2026 |
NGEN |
Results filed (40-F) |
Earnings |
— |
| March 31, 2026 |
DMAC |
Quarterly results filed (8-K) |
Earnings |
— |
| March 31, 2026 |
BCLI |
Quarterly results filed (8-K) |
Earnings |
— |
| March 31, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| March 31, 2026 |
VRTX |
8-K filed: Other event |
Filing |
— |
| March 31, 2026 |
CRDL |
Results filed (40-F) |
Earnings |
— |